EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines

Cleo Anastassopoulou iD, Snežana Medić iD, Stefanos Ferous iD, Fotini Boufidou iD, Athanasios Tsakris iD

Vaccines · 21.01.2025 · 13 (2) · 97

DOI: 10.3390/vaccines13020097 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 21.01.2025. Verfasst von Cleo Anastassopoulou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) causes significant morbidity and mortality, especially in young children and the elderly. RSV vaccine development puzzled vaccinologists for years. Safety concerns of initial formulations, the lack of an absolute correlate of protection, and the need for selecting appropriate virus attenuation and antigen–adjuvant combinations contributed to delayed vaccine production. The recent stabilization of the RSV-F glycoprotein in the prefusion (preF) conformation that constitutes the primary target of RSV-neutralizing antibodies was key for efficient vaccine design. Two protein subunit vaccines (GSK’s Arexvy and Pfizer’s Abrysvo) and one mRNA RSV vaccine (Moderna’s mRESVIA) are now available. This article aims to provide a comparative overview of the safety and efficacy of novel RSV vaccines that are approved for the prevention of RSV-lower respiratory tract disease (LRTD) in adults 60 years of age and older, with updated recommendations calling for the expansion of vaccination to all adults at increased risk for severe RSV disease. Abrysvo is the only vaccine indicated for use in pregnancy to prevent RSV-LRTD in infants from birth to 6 months of age. We provide a comparative assessment of the efficacy of approved RSV vaccines over a maximum of three seasons, summarizing currently available data. We conclude that despite the decreasing vaccine efficacy over time, which should be anticipated for a virus that is characterized by short-term immunity, efficacy was clinically meaningful over placebo. The increased risk of Guillain–Barré syndrome post vaccination with Abrysvo or Arexvy, which prompted the FDA to require the inclusion of such warnings in the prescribing information of these two RSV vaccines, should be prioritized and investigated thoroughly. Furthermore, ongoing vaccine surveillance and further evaluation, particularly among immunocompromised patients, frail elderly subjects, and young infants that were under- or not represented in pivotal clinical trials, are necessary. As in the success story of combined pediatric vaccines, combination vaccines, conferring protection against several respiratory illnesses in one dose, could help improve vaccine acceptance and coverage rates in older adults.

Schlagwörter

Stichwörter der Autor:innen

lower respiratory tract disease (LRTD)maternal immunizationolder adultsprefusion F vaccinerespiratory syncytial virus (RSV)

Autor:innen und Institutionen

  • Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Epidemiology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
  • Center for Disease Control and Prevention, Institute of Public Health of Vojvodina, 21000 Novi Sad, Serbia.
  • Neurochemistry and Biological Markers Unit, 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.

ORCID-Profile: Cleo Anastassopoulou, Snežana Medić, Stefanos Ferous, Fotini Boufidou, Athanasios Tsakris

Zitieren

APA

Anastassopoulou, C., Medić, S., Ferous, S., Boufidou, F., & Tsakris, A. (2025). Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines. Vaccines, 13(2), 97. https://doi.org/10.3390/vaccines13020097

Vancouver

Anastassopoulou C, Medić S, Ferous S, Boufidou F, Tsakris A. Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines. Vaccines. 2025;13(2):97. doi:10.3390/vaccines13020097

BibTeX
@article{Anastassopoulou2025,
  author = {Anastassopoulou, Cleo and Medić, Snežana and Ferous, Stefanos and Boufidou, Fotini and Tsakris, Athanasios},
  title = {Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines},
  journal = {Vaccines},
  year = {2025},
  volume = {13},
  number = {2},
  pages = {97},
  doi = {10.3390/vaccines13020097}
}
Kostenlos starten →